The Impact of Dose Modification and Temporary Interruption of Ibrutinib on Outcomes of Chronic Lymphocytic Leukemia Patients in Routine Clinical Practice

Cancer Medicine - United Kingdom
doi 10.1002/cam4.2998
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Comorbidities Predict Inferior Outcomes in Chronic Lymphocytic Leukemia Treated With Ibrutinib

Cancer
Cancer ResearchOncology
2018English

Beyond Ibrutinib Resistance in Chronic Lymphocytic Leukemia

Cancer therapy & Oncology International Journal
2017English

Autoimmune Cytopenias in Patients With Chronic Lymphocytic Leukaemia Treated With Ibrutinib in Routine Clinical Practice at an Academic Medical Centre

British Journal of Haematology
Hematology
2018English

Anticoagulant Therapy in Patients With Chronic Lymphocytic Leukemia Receiving Ibrutinib

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Three Newly Approved Drugs for Chronic Lymphocytic Leukemia: Incorporating Ibrutinib, Idelalisib, and Obinutuzumab Into Clinical Practice

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2015English

Arresting the Inflammatory Drive of Chronic Lymphocytic Leukemia With Ibrutinib

Clinical Cancer Research
Cancer ResearchOncology
2016English

Persistent Janus Kinase-Signaling in Chronic Lymphocytic Leukemia Patients on Ibrutinib: Results of a Phase I Trial

Cancer Medicine
Cancer ResearchNuclear MedicineRadiologyImagingOncology
2019English

Experience With Ibrutinib in Patients With Refractory and Recurrent B-Cell Chronic Lymphocytic Leukemia

Medical Council
2017English

Phase 2 Study of Acalabrutinib in Ibrutinib-Intolerant Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy